XML 56 R46.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and Licensing Agreements - Additional Information (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 35 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Nov. 30, 2019 USD ($) item | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Nov. 30, 2017 USD ($) | Jun. 30, 2015 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2020 USD ($) | Dec. 31, 2019 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 2,713,000 | $ 3,013,000 | $ 5,762,000 | $ 3,031,000 |  |  |
Unbilled revenue |  |  |  |  |  | 750,000 |  | 750,000 |  |  | $ 750,000 | $ 750,000
Cost of revenue |  |  |  |  |  |  | 600,000 | 141,000 | 600,000 |  |  |
Other |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 1,357,000 | 13,000 | 1,400,000 | 31,000 |  |  |
Astra Zeneca |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  |  |  |  | 0 | 100,000 | 100,000 | 100,000 |  |  |
Cost of revenue, aggregate amount recognized |  |  |  |  |  | 10,600,000 |  | 10,600,000 |  |  | 10,600,000 |
Cost of revenue, Amount Paid |  |  |  |  |  |  |  | 10,600,000 |  |  |  |
Astra Zeneca | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payment per termination agreement |  |  |  |  | $ 75,000,000.0 |  |  | 75,000,000.0 |  |  |  |
2019 KKC Agreement | Kyowa Kirin Co. Ltd |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of pre-clinical study-ready compounds | item | 2 |  |  |  |  |  |  |  |  |  |  |
Number of compounds inhibiting the first undisclosed target | item | 1 |  |  |  |  |  |  |  |  |  |  |
Upfront payment recognized | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |
License fee receivable, first installment | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Term of payment of license fee, first installment | 30 days |  |  |  |  |  |  |  |  |  |  |
License fee receivable, Second instalment | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Term of agreement | 2 years |  |  |  |  |  |  |  |  |  |  |
Initial transaction price | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 1,400,000 |  | 3,700,000 |  |  |  |
Change in estimates |  |  |  |  |  | 0 |  | 0 |  |  |  |
Transaction price allocated to partially unsatisfied performance obligations |  |  |  |  |  | 5,900,000 |  | 5,900,000 |  |  | 5,900,000 |
Uncharged license fees |  |  |  |  |  | 900,000 |  | 900,000 |  |  | 900,000 |
2019 KKC Agreement | Kyowa Kirin Co. Ltd | Minimum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of development candidates | item | 1 |  |  |  |  |  |  |  |  |  |  |
Number of separate collaborative agreements | item | 1 |  |  |  |  |  |  |  |  |  |  |
2017 KKC Agreement | Kyowa Kirin Co. Ltd |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment recognized |  |  |  | $ 30,000,000.0 |  |  |  |  |  |  |  |
Uncharged license fees |  |  |  |  |  |  |  |  |  |  |  | 1,000,000.0
Upfront payment received |  |  |  | 30,000,000.0 |  |  |  |  |  |  |  |
Unbilled revenue |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0
Development milestones received |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |
Commercialization milestones |  |  |  | 80,400,000 |  |  |  |  |  |  |  |
2017 KKC Agreement | Kyowa Kirin Co. Ltd | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development milestones |  |  |  | $ 55,000,000.0 |  |  |  |  |  |  |  |
2017 KKC Agreement | Kyowa Kirin Co. Ltd | Other |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 1,400,000 | 13,000,000 | 1,400,000 | 31,000,000 |  |  |
XuanZhu Agreement | XuanZhu |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 0 |  |  |  |
Upfront payment received | $ 750,000 |  |  |  |  |  |  |  |  |  |  |
License fee recognized | 1,500,000 |  |  |  |  |  |  |  |  |  |  |
Second milestone payment | $ 750,000 |  |  |  |  |  |  |  |  |  |  |
Fosun Agreement | Fosun Pharma |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment recognized |  |  | $ 12,000,000.0 |  |  |  |  |  |  | $ 12,000,000.0 |  |
Revenue |  |  |  |  |  | 0 | 300,000.0 | 0 | 300,000.0 |  |  |
Future development milestones |  |  |  |  |  |  |  |  |  | $ 110,000,000.0 |  |
Fosun Agreement | Fosun Pharma | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Threshold percentage of net sales for tiered royalties |  |  | 20.00% |  |  |  |  |  |  |  |  |
Knight Agreement | Knight |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 0 | $ 0 | $ 700,000 | $ 0 |  |  |
Upfront payment received |  | $ 2,300,000 |  |  |  |  |  |  |  |  |  |
Knight Agreement | Knight | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Future development milestones |  | $ 16,400,000 |  |  |  |  |  |  |  |  |  |
Development and Commercialization | Astra Zeneca |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty revenue (as a percent) |  |  |  |  | 10.00% |  |  |  |  |  |  |
Percentage of non royalty revenue (as a percent) |  |  |  |  | 20.00% |  |  |  |  |  |  |

X
- Definition The amount of initial transaction price. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsInitialTransactionPrice
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of licenses fee recognized during the period. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsLicenseFee
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration and licensing agreements, payment per termination agreement. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsPaymentPerTerminationAgreement
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of second milestone payment recognized during the period. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsSecondMilestonePayment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of license fee recognized during the period. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontPaymentReceivable
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of license fee receivable in first installment during the period. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontPaymentReceivableFistInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of license fee receivable in second installment during the period. + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontPaymentReceivableSecondInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of commercialization milestones payment to be received under collaborative arrangements. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementCommercializationMilestonesPaymentToBeReceived
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of development milestone payment received to date. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementDevelopmentMilestonesPaymentReceived
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of development milestones payment to be received under collaborative arrangements. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementDevelopmentMilestonesPaymentToBeReceived
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of future development and commercialization milestone under collaborative arrangements. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementFutureDevelopmentAndCommercializationMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cost of revenue, aggregate amount recognized. + References No definition available. + Details
Name: | ardx_CostOfRevenueAggregateAmountRecognized
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of compounds inhibiting the first undisclosed target. + References No definition available. + Details
Name: | ardx_NumberOfCompoundInhibitingFirstUndisclosedTarget
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of development candidates. + References No definition available. + Details
Name: | ardx_NumberOfDevelopmentCandidates
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of pre-clinical study-ready compounds. + References No definition available. + Details
Name: | ardx_NumberOfPreClinicalStudyReadyCompounds
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of separate collaborative agreements. + References No definition available. + Details
Name: | ardx_NumberOfSeparateCollaborativeAgreements
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the cash outflow from payments of uncharged license fees. + References No definition available. + Details
Name: | ardx_PaymentsOfUnchargedLicenseFees
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents percentage of non-royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfNonRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of change in estimate of revenue to be recognized during the period. + References No definition available. + Details
Name: | ardx_RevenueFromContractWithCustomerChangeInEstimate
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Term of agreement. + References No definition available. + Details
Name: | ardx_TermOfAgreement
Namespace Prefix: | ardx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of payment of first installment fee. + References No definition available. + Details
Name: | ardx_TermOfPaymentOfLicenseFeeFirstInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the threshold percentage of net sales for tiered royalties. + References No definition available. + Details
Name: | ardx_ThresholdPercentageOfSalesForTieredRoyalties
Namespace Prefix: | ardx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Transaction price allocated to partially unsatisfied performance obligations. + References No definition available. + Details
Name: | ardx_TransactionPriceAllocatedToPartiallyUnsatisfiedPerformanceObligations
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ardx_OtherProductOrServicesRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_AstrazenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementCertainSpecificPatentAndPatentApplicationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_XuanzhuHKBiopharmaceuticalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_DevelopmentAndCommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |